boston scientific - search results

If you're not happy with the results, please do another search
boston featured

Boston Scientific announces partial acquisition offer for majority stake of Acotec Scientific

Boston Scientific has announced that it will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares...
truveta

Truveta announces collaboration with Boston Scientific to advance post-procedure patient insights and help address...

Truveta announced a strategic collaborative agreement with Boston Scientific to improve long-term patient care and gain insights into healthcare disparities. Through this collaboration, Boston...
boston featured

Boston Scientific announces acquisition of Obsidio

Boston Scientific has announced the acquisition of Obsidio, a privately held company that has developed the Gel Embolic Material (GEM) technology used for embolization...
boston featured

Boston Scientific announces agreement to purchase majority stake of M.I.Tech from Synergy Innovation

M.I.Tech is the creator of the HANAROSTENT technology, a family of conformable, non-vascular, self-expanding metal stents, which have been distributed by Boston Scientific in...
embold

Boston Scientific Receives FDA Clearance for the EMBOLD Fibered Detachable Coil

Boston Scientific has received US Food and Drug Administration (FDA) 510(k) clearance for the EMBOLD Fibered Detachable Coil, which is indicated to obstruct or...

Boston Scientific announces agreement to acquire Devoro Medical

Today, Boston Scientific announced an agreement to acquire Devoro Medical, developer of the Wolf thrombectomy platform. The non-console and lytic-free Wolf technology targets and...

Boston Scientific initiates randomised controlled trial for the EkoSonic endovascular system

Boston Scientific has commenced enrolment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the...

Boston Scientific announces European launch of SpaceOAR Vue Hydrogel

Boston Scientific has initiated the European launch of its SpaceOAR Vue Hydrogel, which is designed to create a temporary space between the prostate and the...
TheraSphere

Boston Scientific receives FDA approval for TheraSphere Y-90 glass microspheres

The US Food and Drug Administration (FDA) have granted approval of the TheraSphere Y-90 glass microspheres (Boston Scientific), developed for the treatment of patients...
acquisition

Boston Scientific agrees to divest BTG Specialty Pharmaceuticals business

Boston Scientific has announced that it has entered into a definitive agreement with Stark International and SERB SAS, affiliates of the European specialty pharmaceutical...

Boston Scientific receives FDA approval for the Ranger DCB

Boston Scientific announced it has received US Food and Drug Administration (FDA) approval of the Ranger drug-coated balloon (DCB), developed for the treatment of...

VIVA 2019: Boston Scientific announces positive data for the Ranger DCB and the Eluvia...

Boston Scientific today announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at the 2019...
innovation

“Collaboration and innovation” is at core of Michael Jaff’s new role at Boston Scientific

Boston Scientific recently announced that vascular medicine specialist Michael R Jaff (Newton-Wellesley Hospital, Newton, USA) will be joining the company as vice president, clinical...
innovation

Michael Jaff joins Boston Scientific to drive innovation in peripheral technologies

Michael R Jaff is to be vice president, clinical affairs, innovation and technology, peripheral interventions of Boston Scientific by January 2020. In this role,...
acquisition

Boston Scientific closes acquisition of BTG

Boston Scientific has announced the completion of its acquisition of BTG, pursuant to the previously announced scheme of arrangement. BTG develops and commercialises products...
Mayo

Boston Scientific signs medical technology alliance with Mayo Clinic

Medical devices manufacturer Boston Scientific has partnered with Mayo Clinic, a non-profit academic medical centre, to launch an accelerator focused on medical solutions for...

Varian Medical acquires two Boston Scientific product lines

Radiation therapy firm Varian Medical Systems has signed an agreement to acquire Boston Scientific's portfolio of drug-loadable microsphere and bland embolic bead products designed...
vici

Boston Scientific launches new stent for venous obstructive disease

Boston Scientific has won FDA approval for its Vici Venous Stent System for the treatment of iliofemoral venous obstructive disease. The device received CE mark...
medtronic

Medtronic and Boston Scientific stand by paclitaxel devices despite Katsanos’ critical study

Speaking to investors at the JP Morgan healthcare conference in San Francisco, executives from Medtronic and Boston Scientific said their data do not show...
acquisition

Boston Scientific announces recommended offer to acquire BTG

Boston Scientific has announced it has reached an agreement on the terms of a recommended offer to acquire BTG, a company headquartered in the...
SpaceOAR

Boston Scientific announces agreement to acquire Augmenix

  Boston Scientific has announced that it has entered into a definitive agreement to acquire Augmenix, a privately-held company which has developed and commercialised the...

Boston Scientific announces agreement to acquire Veniti

Boston Scientific has signed an agreement to acquire Veniti, a privately-held company in Fremont, USA which developed and commercialised the Vici venous stent system for...

Positive results for Boston Scientific Ranger paclitaxel-coated PTA balloon catheter

Positive results from the RANGER SFA trial for Boston Scientific’s Ranger paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter have been presented at the 2017...

Boston Scientific receives CE mark for Eluvia drug-eluting stent, begins IMPERIAL trial

Boston Scientific has received CE mark for the Eluvia drug-eluting vascular stent, and is to begin commercialisation of the product immediately. The company has also received Investigational Device Exemption to asses the Eluvia vs the Zilver PTX (Cook Medical).

Boston Scientific to acquire CeloNova’s interventional radiology business

The transaction, consisting of an upfront payment of US$70 million and additional payments contingent on regulatory and sales milestones, will expand Boston Scientific‰Ûªs interventional oncology portfolio with drug-eluting microspheres and spherical embolics.

Boston Scientific announces definitive agreement to acquire Bayer’s Interventional Division

The US$415 million cash acquisition is expected to strengthen Boston Scientific‰Ûªs peripheral interventions business and accelerate growth in peripheral atherectomy and thrombectomy categories.

Boston Scientific launches OffRoad re-entry catheter in USA

Boston Scientific has announced the US launch and first use of the OffRoad re-entry catheter system. The system provides a new option to treat chronic total occlusions in the femoropopliteal arteries.

Boston Scientific’s Vessix renal denervation system

Here is an animation of Boston Scientific’s Vessix renal denervation system. Boston Scientific CEO Mike Mahoney was quoted by Qmed as being "optimistic" about...

Boston Scientific completes enrolment in SuperNOVA trial

The SuperNOVA trial is a global, single-arm, prospective, multicentre trial evaluating the long-term (12 month) safety and effectiveness of the Innova stent system.
Interventional News for specialists

Boston Scientific announces its support activities for Awareness of Colorectal Cancer Month

On 13 March 2013 Boston Scientific announced it is supporting several public education initiatives throughout March to highlight the prevalence and prevention of cancers...

Boston Scientific launches Rubicon Support Catheter in 0.035″ and 0.018″ diameters

The Rubicon Support Catheter has been made available in the USA in diameter sizes 0.035" and 0.018", which are intended to improve the treatment of peripheral arterial disease.
Interventional News for specialists

Boston Scientific Carotid Wallstent found safe in study of high surgical risk patients

Results from the CABANA post-approval study demonstrated that carotid artery stenting with Carotid Wallstent and FilterWire EZ (Boston Scientific) is a safe alternative to carotid endarterectomy in patients with carotid artery stenosis who are at increased risk for surgery.
Interventional News for specialists

Aptus Endosystems appoints former CEO of Boston Scientific as new board member

James R Tobin served as president and CEO of Boston Scientific from March 1999 to July 2009 when the company‰Ûªs revenues grew from more than US$2 billion to over US$8 billion.
Interventional News for specialists

Boston Scientific completes clinical trial enrolment for Adapt Monorail carotid stent system

The ASTI post-market clinical follow-up trial is designed to evaluate the Adapt Monorail carotid stent system in combination with the FilterWire EZ embolic protection system for treatment of carotid artery disease in patients at high risk for carotid surgery.
Interventional News for specialists

Boston Scientific launches Mustang PTA balloon catheter globally

On June 20, Boston Scientific announced the global launch of its Mustang PTA balloon catheter, a highly deliverable 0.035 inch percutaneous transluminal angioplasty (PTA) catheter designed for a wide range of peripheral angioplasty procedures.
Interventional News for specialists

Boston Scientific completes enrolment in the ORION clinical trial evaluating the Epic stent to...

The next generation EPIC stent is a self-expanding nitinol stent designed to sustain vessel patency, while providing enhanced visibility and accuracy during placement.
Interventional News for specialists

Boston Scientific announces global launch of Journey Guidewire

Boston Scientific Corporation has announced the global launch of its Journey Guidewire, an innovative 0.014‰Û guidewire designed for use in challenging, small vessel peripheral angioplasty procedures.
Interventional News for specialists

Boston Scientific announces enrollment of first patient in benign stricture study of WallFlex biliary...

Boston Scientific Corporation has announced that the first patient has been enrolled in a clinical trial to evaluate its WallFlex biliary RX fully covered stent for the treatment of benign bile duct strictures
Interventional News for specialists

Boston Scientific announces FDA clearance and CE mark for WallFlex fully covered oesophageal stent

Complete portfolio of the company‰Ûªs WallFlex stent family of self-expanding metal stents now available in US, Europe and other international markets

Medtronic names Laura Mauri as new chief scientific, medical and regulatory officer

Medtronic has announced that Laura Mauri has been appointed as the company’s chief scientific, medical and regulatory officer. This appointment adds to Mauri's prior responsibilities...
Interventional News for specialists

Live from CIRSE 2015: Twelve-month results from the MAJESTIC trial showed primary patency rate...

On the back of these results, Stephan MÌ_ller-HÌ_lsbeck announced the commencement of an international multicentre randomised controlled trial that will compare the Eluvia drug-eluting vascular stent system (Boston Scientific) with Zilver PTX, the drug-eluting stent system from Cook Medical. The principal investigators will be MÌ_ller-HÌ_lsbeck (Flensburg, Germany) and William Gray (New York, USA).

Direxion Torqueable Microcatheter gets FDA nod and CE mark approval

Boston Scientific has announced receiving US Food and Drug Administration (FDA) clearance and CE mark approval for the Direxion Torqueable Microcatheter, which is designed to suit a range of peripheral embolization procedures.

REDUCE-HTN data show significant and sustained blood pressure reduction with Vessix

New data presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco, USA, demonstrate an excellent safety profile for Boston Scientific‰Ûªs renal denervation system.

MAJESTIC trial to evaluate Innova drug-eluting stent system in superficial femoral artery lesions

The MAJESTIC trial, designed to evaluate the safety and performance of the Boston Scientific‰Ûªs peripheral drug-eluting stent system, is projected to enroll 55 patients across 15 centres in Europe, Australia and New Zealand.

WallFlex Biliary RX Fully Covered Stent study enrols first patient

The multicentre, prospective, randomised study will compare the WallFlex Biliary RX Fully Covered self-expanding metal stent (Boston Scientific) to plastic stents for the treatment of benign bile duct strictures caused by chronic pancreatitis.

FDA limits use of Wingspan stent in patients with intracranial stenosis

The US Food and Drug Administration (FDA) has announced changes to the labeling, including to the indications for use of the Wingspan stent (Boston Scientific/Stryker), which limit its use to a narrow, select group of patients diagnosed with intracranial stenosis.
Interventional News for specialists

ORION trial reports positive clinical outcomes for the Epic stent in iliac arteries

The Epic stent (Boston Scientific) demonstrated a low nine-month major adverse events rate of 3.4% in the intent-to-treat population, which was significantly lower than the pre-specified performance goal of 17% (p<0.001) based on historical published outcomes for iliac stenting.
Interventional News for specialists

PolarCath dilatation system reduces restenosis rates by 47% in peripheral stenting procedures

The COBRA trial enrolled 76 patients with 90 superficial femoral artery lesions who were randomised to CryoPlasty therapy with the PolarCath system (Boston Scientific) or conventional balloon angioplasty for post-dilation of nitinol stents used to treat superficial femoral artery blockages.
Interventional News for specialists

SuperNOVA international clinical trial begins patient enrolment

SuperNOVA is an international, prospective, single-arm, non-randomised trial evaluating the safety and effectiveness of the Innova self-expanding bare-metal stent system (Boston Scientific) in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).
Interventional News for specialists

FDA approves Renegade HI-FLO Fathom Pre-Loaded system for peripheral embolization procedures

The Boston Scientific‰Ûªs system will primarily be used by interventional radiologists for minimally invasive procedures to treat uterine fibroids and liver cancer.
Interventional News for specialists

FDA approves Renegade HI-FLO Fathom Pre-Loaded system for peripheral embolization procedures

The Boston Scientific‰Ûªs system will primarily be used by interventional radiologists for minimally invasive procedures to treat uterine fibroids and liver cancer.
Interventional News for specialists

New uterine fibroid embolization study goes against the grain in finding Contour SE comparable...

Boston Scientific‰Ûªs spherical embolisation agent is able to provide adequate uterine fibroid infarction. Richard Shlansky-Goldberg presented the data at a satellite symposium organised by the company at CIRSE 2010.

SIO announces first site approved for enrolment in ACCLAIM clinical trial

The Society of Interventional Oncology (SIO) announces Mayo Clinic as the first site approved and activated for enrolment on the society’s primary clinical trial...
TOP 10

Interventional News’ top 10 most popular stories of December 2022

Interventional News’ most popular stories as 2022 came to a close included news of a US Food and Drug Administration clearance for a new...
TOP 10

Interventional News’ top 10 most popular stories in 2022

Interventional News covered a whole range of the specialty's news during 2022, but readers' attention was most piqued by acquisitions (Boston Scientific's of Obsidio...

BSIR faculty highlights specialty developments worth watching

In the opening session of the British Society of Interventional Radiology (BSIR) annual scientific meeting 2022 (2–4 November, Glasgow, UK) titled ‘What’s up, Doc?’,...

The rebirth of transarterial radioembolization and the crucial role of the IR

After the disappointment of a few failed randomised controlled trials (RCTs), transarterial radioembolization (TARE) is finally back in the spotlight. And interventional radiologists (IRs)...

SAVAL trial finds no gains with custom drug-eluting stents in PAD below the knee

Day one of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting (10–14 September, Barcelona, Spain) put a strong focus on...
TOP 10

Interventional News’ top 10 most read items of August 2022

Interventional News' popular stories last month included acquisitions by Boston Scientific and Gore, studies of deep vein thrombosis and peripheral arterial disease treatments and,...

Vascular experts establish appropriate use of IVUS in peripheral interventions

Royal Philips today announced an important milestone in the evolving standard of care for treating patients with peripheral vascular disease: the establishment of the...

Interventional News’ top 10 most read articles of June 2022

Among the most popular pieces from last month are reports on papers delivered at the Society of Interventional Radiology (SIR) 2022 Annual Meeting (11–16...
vascular tim clark

The vascular biology behind endovascular therapies

Peripheral arterial disease (PAD) produces a global health burden and remains a leading cause of disability, limb loss and reduced quality of life. PAD...
TOP 10

Interventional News’ top 10 most popular stories of May 2022

May's top 10 stories on Interventional News include a report of long-term data on the safety of femoropopliteal endovascular treatment with paclitaxel-coated devices, FDA clearance of...

Evidence in the SFA: DES ‘will be the standard of care’ when treating SFA...

NOTE: This video is ONLY available to watch in selected countries and geographies Marianne Brodmann (Medical University of Graz, Division of Angiology, Austria) talks...

Dedicated vs. non-dedicated: Researchers place venous stenting under the spotlight at AVF 2022

Venous stenting was a hot topic on the agenda of the recent American Venous Forum (AVF) annual meeting (23–26 February, Orlando, USA). Catching the audience’s...

Evidence in the SFA: Eluvia has a “significantly better” patency rate compared to conventional...

NOTE: This video is ONLY available to watch in selected countries and geographies Gunnar Tepe (interventional radiologist, Germany) discusses the results and subsequent impact...

Evidence in the SFA: Considering the data when making decisions for patients

NOTE: This video is ONLY available to watch in selected countries and geographies  Koen Deloose (vascular surgeon, Belgium) looks at the evidence needed in order...

Evidence in the SFA: What kind of stent should we use?

NOTE: This video is ONLY available to watch in selected countries and geographies Antonio Micari (interventional cardiologist, Italy) gives his thoughts on the EMINENT...

Evidence in the SFA: Best strategy for treatment of the femoropopliteal segment

NOTE: This video is ONLY available to watch in selected countries and geographies  Yann Goueffic (vascular surgeon, France) discusses the evidence that is needed...

Jeremy Durack and John Simpson to join Cordis-X innovation accelerator

Ajax Health has announced the appointments of two cardiovascular professionals to Cordis-X, an independent accelerator created to drive innovation and growth to Cordis.  "Since the...

Time matters in the trauma setting

NOTE: This video is ONLY available to watch in selected countries and geographies  With trauma comes the challenge of not knowing what a patient is...
TheraSphere treatment

EPOCH trial reignites radioembolization as treatment for colorectal liver metastases

In the trial, radioembolization (also called selective internal radiation therapy ) using glass beads (Therasphere; Boston Scientific) containing radioactive yttrium (Y-90) was used as...
Interventional News

Interventional News’ top 10 most popular stories of November 2021 

November’s top 10 features a pilot study regarding cryoablation for the treatment of early-stage, low-risk breast tumours, as well as data indicating that the Ellipsys vascular access...
Interventional News

Interventional News’ top 10 most popular stories of October 2021   

October’s top 10 features an interview with Maureen Kohi (Chapel Hill, USA), the chair and professor of Radiology (University of North Carolina), and the...

SIO announces ACCLAIM clinical trial with support from industry partners

The Society of Interventional Oncology (SIO) has announced the launch of the society’s first clinical trial—Ablation with confirmation of colorectal liver metastases (ACCLAIM) prospective...
Philips

Philips announces large-scale study outcomes on use of IVUS in peripheral interventions

Royal Philips today announced the results of a new large-scale real-world analysis of Centers for Medicare & Medicaid Services (CMS) data on the health...

EMINENT one-year results show “superior” primary patency rate for Eluvia DES compared to bare...

One-year results presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October, Las Vegas, USA) from the EMINENT trial demonstrated the superiority of the Eluvia...

Two-year Ranger DCB data demonstrate “sustained, high rate” of device efficacy

Patients treated with the Ranger drug-coated balloon (DCB; Boston Scientific) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year...
EkoSonic

Positive data for the EkoSonic endovascular system presented at VIVA 2021

Boston Scientific announced positive results for the EkoSonic endovascular system (EKOS system) during a late-breaking clinical trial presentation at Vascular Interventional Advances (VIVA) 2021...

Late-breaking data indicate improved progression-free survival following TheraSphere treatment

Late-breaking trial data has demonstrated improved progression-free survival in patients with metastatic colorectal cancer after treatment with TheraSphere Y-90 Glass Microspheres (Boston Scientific). Findings from...

How it’s made: Interlock and IDC Detachable Coils

NOTE: This video is ONLY available to watch in selected countries and geographies In case of embolisation, Interlock and IDC Detachable Coils (Boston Scientific)...
CLTI

New tools on the horizon for CLTI patients revealed at ISET 2021

“I am going to give you reasons to be excited about your critical limb practice,” Peter Schneider (University of California San Francisco, San Francisco,...
dillon brown bifurcated t-stent reconstruction

Bifurcated T-stent reconstruction is safe and effective treatment for HVOO in orthotopic liver transplant...

A study has found that bifurcated T-stent reconstruction offers a safe and effective treatment option for hepatic venous outflow obstruction (HVOO) with anastomotic stenoses...

Trialists’ insights on the 2-year results from the COMPARE trial

NOTE: This video is ONLY available to watch in selected countries and geographies  Sabine Steiner (Leipzig, Germany) sits down with Michael Jaff, the CMO...
interventional

Interventional News’ top 10 most popular stories for February 2021

Our top 10 stories of February 2021: a success story for interventional oncology as intra-arterial delivery of chemotherapeutic agents is shown to improve survival,...

ControlRad Select imaging system gains FDA market clearance

ControlRad has announced US Food and Drug Administration (FDA) 510(k) clearance to market ControlRad Select, a technology that utilises proprietary semi-transparent filters, a user-interface...
SIRT

NICE recommends selective internal radiation therapies for the treatment of hepatocellular carcinoma

The National Institute for Health and Care Excellence (NICE) has issued guidance recommending the use of selective internal radiation therapy (SIRT) for the treatment...
ROWAN

New trial investigating combination therapy of radioembolization and immunotherapy in HCC patients launches

The Society of Interventional Oncology (SIO) and Boston Scientific have announced a new multicentre, prospective, randomised trial to study combination therapy of radioembolization and...

Personalised treatment planning “the future” of radioembolization, ECIO hears, in Y-90 vs. Ho-166 comparison

Personalised treatment selection and planning based on controlled dosimetry will lead to improvements in treatment accuracy. This is the conclusion presented by Marnix Lam...

LINC 2021: Head-to-head trials take centre stage in drug-eluting technology late-breaking session

Data from two head-to-head trials on drug-eluting technologies in femoral artery treatment were presented during a late-breaking session at LINC 2021 (Leipzig Interventional Course;...

Paclitaxel situation “crystallising” thanks to new data and teamwork, VIVA audience hears

This year's Vascular Interventional Advances annual meeting (VIVA 2020; 6–8 November, online) opened with a session on controversial hot topics and advanced multidisciplinary approaches...

Sinomed announces positive safety and efficacy data from PIONEER III study

Sinomed has announced the presentation of data from its inter-continental PIONEER III study comparing the safety and efficacy of the Supreme HT (healing-targeted) drug-eluting...
reimbursement

Calls in Germany for reimbursement as analysis shows drug-eluting technology is cost-effective

Stefan Müller-Hülsbeck (Ev Luth Diakonissenanstalt zu Flensburg, Flensburg, Germany) presented attendees of the online meeting of the Cardiovascular and Interventional Radiological Society of Europe...

CMS grants additional reimbursement for the Eluvia drug-eluting vascular stent system

Boston Scientific announced that the US Centers for Medicare and Medicaid Services (CMS) granted a new technology add-on payment (NTAP) for the Eluvia drug-eluting...
radioembolization

Novel use of Y-90 radioembolization could transform prostate cancer treatment

In an entirely new endeavour for Yttrium-90 (Y-90) radioembolization, investigators from Northwestern University, Chicago, USA, have used the technique for the treatment of prostate...
interventional oncology

Interventional Oncology 2.0: Soul-searching to define our identity

Julius Chapiro and Lynn Savic claim there is “no need for scepticism” about the recent emergence and growth of immuno-oncology from an interventional oncologists’...
SeQure®

A decade of PAE data demonstrates the procedure’s safety and efficacy: “Its time is...

Ten-year data published in Radiology show that prostate artery embolization (PAE) is a safe and effective treatment for men with benign prostatic hyperplasia (BPH),...

MHRA: Warning to be added to paclitaxel device IFUs in Europe

In a new field safety notice, the UK Medicines and Healthcare products Regulatory Agency (MHRA) states that a warning and clinical summary section will...

CX 2020 LIVE: Strong support for relining peripheral arteries and rivaroxaban use for widespread atherosclerosis 

In a series of Podium 1st presentations from world-class faculty, CX 2020 LIVE attendees heard the latest data on peripheral arterial disease management and an evaluation of different types of stents, including...

CX 2020 LIVE pioneers virtual vascular conference format in COVID-19 era

CX 2020 LIVE came to life online—despite COVID-19—using state-of-the art broadcast technology to bring together more than 1,000 vascular specialists, live, from 95 countries across...
ELUVIA

Endovascular intervention for the treatment of femoropopliteal lesions: ELUVIA is safe and effective

This advertorial is sponsored by Boston Scientific. Boston Scientific leads the largest clinical programme investigating drug-eluting therapy for the treatment of peripheral arterial disease (PAD),...

CIRSE 2019: Hear the latest from clinical trials comparing paclitaxel technologies head-to-head

NOTE: ONLY intended for healthcare professionals outside of the USA and France. Zoom in on a tête-à-tete between Marianne Brodmann (Graz, Austria) and Giovanni Torsello...

US FDA panel reviews paclitaxel device data: No recommendations issued

The US Food and Drug Administration (FDA) convened today and yesterday for a General Issues Panel Meeting on the late mortality safety signal associated...
antibiotics

Pilot study finds post-UFE antibiotic use does not affect infection rates

Post-procedural antibiotic use does not significantly affect infectious complication rates following uterine fibroid embolization (UFE), a recent pilot study concludes. Presenting these data at...

Only Eluvia Uses a Polymer for Controlled, Targeted Delivery of the Lowest Drug Dose

Eluvia DES is the only technology that uses polymer-based drug delivery to treat Peripheral Artery Disease (PAD). Its polymer ensures that the majority of...
PAE

IR community backs PAE and calls for close collaboration with urologists

Current evidence supports the use of prostate artery embolization (PAE) as a safe, effective, and minimally-invasive treatment for the symptoms of benign prostatic hyperplasia...
shoulder

Embolization registry will use artificial intelligence to predict patient outcomes

Sandeep Bagla (chair of Interventional Radiology at the Vascular Institute at Virginia, Woodbridge, USA) presented the results of an initial clinical study detailing his...

Eluvia drug-eluting stent continues to demonstrate positive outcomes in IMPERIAL trial sub-analyses

Boston Scientific has announced results from sub-analyses of the IMPERIAL clinical trial for the Eluvia Drug-Eluting Vascular Stent System. Data demonstrated that the efficacy...

Hear the latest thoughts on paclitaxel from global experts: Their current practice and patient...

 Following the latest information presented at the Charing Cross (CX) International Symposium related to the meta-analysis of paclitaxel-coated devices (Katsanos et al), hear from a...
drug delivery

0.018-inch drug delivery platforms are as effective as 0.035-inch devices

Interventionists can confidently use lower profile drug delivery platforms, based on data that show 0.018-inch guidewire devices are noninferior to 0.035-inch guidewires. In a...
women

GEMS programme launches to promote diversity in IR specialty

The Society of Interventional Radiology (SIR) announced the establishment of the Grants for Education of Medical Students (GEMS) programme at its 2019 annual scientific...
paclitaxel

Paclitaxel-releasing devices: An unfolding story

Paclitaxel Timeline: Meta-analysis finds a higher risk of death in the long term when paclitaxel-coated devices are used in the leg Without additional long-term...
FDA

US FDA continues to investigate paclitaxel devices in the leg

A meta-analysis published in the Journal of the American Heart Association (JAHA) late last year by Konstantinos Katsanos (Patras, Greece) and colleagues, suggesting an...

Vascular Leaders Forum discussions seek consensus on paclitaxel

The Vascular Leaders Forum (VLF, 1–2 March, Washington DC, USA), hosted by the non-profit organisation VIVA Physicians, is a special consortium which was called...
Interventional News for specialists

Vici stent meets primary endpoints in VIRTUS 12-month data

New 12-month data from the VIRTUS trial demonstrate that patients who were treated with the Vici venous stent system (Boston Scientific) for iliac and...

Positive outcomes for Eluvia stent in long lesion IMPERIAL sub-study

Clinical outcomes from the IMPERIAL Long Lesion Sub-study were presented at VIVA (5–8 November, Las Vegas, USA) demonstrating that the Eluvia drug-eluting vascular stent...

New resorbable embolic agent for uterine fibroid embolization is effective

A new, spherical resorbable gelatine embolic agent, GelBead, has been shown to be “very effective” for uterine fibroid embolization (UFE). Nigel Hacking (Department of...

Eluvia outperforms Zilver PTX in IMPERIAL 12-month results

The Eluvia drug-eluting vascular stent system (Boston Scientific) shows superior primary patency compared to the Zilver PTX drug-eluting stent (Cook Medical), concludes the 12-month...
Barry Katzen

Move to less invasive medicine is “one of the greatest shifts in medical history”

“Innovation has driven my life in interventional radiology—and what a ride it has been,” said Barry Katzen, founder and chief medical executive of Miami...

ABK Biomedical appoints Michael J Mangano as president and CEO

ABK Biomedical, a company dedicated to the research, development and commercialisation of innovative embolic therapies, has announced the appointment of Michael J Mangano as...
Embolics

Flowing on the horizon: Liquid embolics in development

To become a mainstay liquid embolic for peripheral use, an optimal product should be easy to use, have reproducible and controllable deep penetration for...

Artificial intelligence will support clinical decision making in interventional oncology

Aaron Abajian and Julius Chapiro, New Haven, USA, write about results from an early experiment in applying artificial intelligence (AI) and machine learning as a...
Purple Embozene microspheres

Embozene microspheres are now indicated for prostate artery embolization

Boston Scientific showed at the Global Embolization Cancer Symposium and Technologies (GEST US; 17–19 May, Miami Beach, USA) meeting that the US Food and...

First data from head-to-head comparison of Ranger and IN.PACT drug-coated balloons presented at LINC

Early data from the first randomised controlled trial to compare two drug-coated balloons (DCBs) suggest that the primary patency obtained with the Ranger DCB...
Andrew Holden

Andrew Holden

“If you are clinically skilled, achieve a high level of technical training in interventional radiology procedures, have the best audited results for a procedure...
Innovation from interventional inventors

Persistence, persistence, persistence: Lessons in device innovation from three prolific inventors

Timothy Clark, director of Interventional Radiology at Penn Presbyterian Medical Center, Philadelphia, USA and co-founder and chief executive officer of Forge Medical, which has...

Eluvia paclitaxel-eluting stent shows long-term freedom from revascularisation at three years

Boston Scientific has announced the three-year results from the MAJESTIC trial for the Eluvia paclitaxel-eluting vascular stent system at the Cardiovascular and Interventional Radiological...

Same day Y-90 treatment could become paradigm of the future

While further refining where radioembolization should optimally lie in current treatment paradigms for the most common liver-confined or liver-dominant cancers is important, a honing...

Lipiodol—an effective imaging biomarker for chemoembolization of hepatocellular carcinoma

Beyond embolization endpoints under fluoroscopic guidance, the introduction and standardisation of cone-beam CT imaging in the procedure room has allowed Lipiodol (Guerbet) to become...
PAE

Women with fibroids see significant improvement in sexual function one year after embolization

A study published online ahead of print in CardioVascular and Interventional Radiology (CVIR) has demonstrated that at one year, uterine fibroid embolization significantly improves...

MIRACLE I demonstrates high tumour control rate for drug-eluting microspheres

Goetz Richter, Clinic for Diagnostic and Interventional Radiology, Stuttgart, Germany, presented breaking data from the Miracle 1 multicentre hepatocellular carcinoma trial at The Symposium...

ATTRACT fails to meet primary endpoint, but experts agree results are “hypothesis-generating”

Data from the randomised controlled ATTRACT trial revealed that the addition of catheter-based intervention to standard-of-care anticoagulation failed to significantly decrease the occurrence of...

Gireesh Mukund Warawdekar

“Interventional radiology has always been characterised by its innovative spirit. We are now seeing progress with new procedures being developed to create percutaneous arteriovenous fistulae....
Interventional News for specialists

Top tips on using coils and plugs in embolization

By Rahul S Patel and Richard Tapnio Coils and plugs are among the most commonly employed tools for vessel sacrifice and aneurysmal occlusion. In practice, these tools...

Two-year MAJESTIC data show sustained positive results for Eluvia drug-eluting stent

The MAJESTIC trial set out to evaluate the performance of the Eluvia paclitaxel-eluting vascular stent system (Boston Scientific) in the treatment of femoropopliteal artery...

Promising findings for novel drug-eluting peripheral stent

A new animal study, presented at EuroPCR (17–20 May, Paris), indicates that a novel, fluoropolymer-coated, self-expanding, paclitaxel-eluting peripheral stent (Eluvia, Boston Scientific) is associated...
Interventional News for specialists

NICE provides positive guidance on use of GreenLight XPS laser therapy system in benign...

Boston Scientific has announced that its GreenLight XPS laser therapy system, used for the treatment of prostatic enlargement, known as benign prostatic hyperplasia, received...
Interventional News for specialists

Key clinical questions I would like to see answered in the future of deep...

Therapies in deep venous thrombosis (DVT) have been slow to advance over the past 50 years. Recently, growing awareness and improvements in tools and...
Interventional News for specialists

Spectranetics Names Udo Scheiner as senior vice president of international operations

Udo Scheiner has been named Spectranetics’ senior vice president of international operations, effective as of 23 March. In this role, Scheiner will report directly to Scott Drake,...
Interventional News for specialists

NuCryo Vascular gets 510(k) clearance for next generation reusable Polarcath peripheral dilatation system

NuCryo Vascular has announced receiving 510(k) clearance on the next generation reusable Cryoplasty inflation device. The company has also announced that it will be selling the current and next generation model via a direct sales team.

Modern regimens of thrombolysis usually safe

While presenting on the trials and updates in deep vein thrombosis, Stephen Kee told delegates at CIRSE 2015 that there was ‰ÛÏan information overload‰Û when Pubmed was searched for ‰ÛÏdeep vein thrombosis‰Û.

Gabriel Bartal

“In the early days, I used to have to cut a 7F plastic tube, make side holes, send it off for sterilisation and shape...

We “still await” the ideal venous stent, despite rapid development in technology

Today, venous stenting plays an important role in the treatment of deep venous pathologies. The current indications for the use of venous stents include...

Lindsay Machan

“Interventional radiologists should not be cavalier about protecting ideas, but focusing on maximising rewards has sidelined more ideas than it has helped individual inventors....

New minimally invasive technique to treat varicose veins shows early promise

A research group from Italy has recently detailed their early experience using one-shot scleroembolization to treat varicose veins of the lower extremities.

Multicentre audit shows lifesaving role of 24/7 interventional radiology

This new data reveals the importance of access to 24/7 interventional radiology and the need to ensure availability of interventional radiologists in emergency care. There is a wide variation in the availability of 24/7 interventional radiology across the UK, which means that patients in some parts of the country do not receive the benefits of minimally invasive modern medicine in the emergency setting.

Adapt carotid stent is a “safe and effective alternative” to carotid endarterectomy

In a late-breaking abstract session at CIRSE 2012, Marc Bosiers presented the results of the ASTI trial, which showed the Adapt carotid stent to be a safe and effective treatment for patients with carotid artery stenosis who are at high-risk of carotid endarterectomy. Interventional News also made a round-up of other late-breaking studies on renal denervation and arterial embolization.

What all interventional radiologists should know about spherical particles

At the GEST 2012 US meeting in New York, USA, James B Spies, Georgetown University Hospital, Washington DC, USA, outlined the basic properties of spherical particles.

Bariatric gastric artery embolization can modulate “hunger hormone” levels

Charles Kim, Durham, USA, and colleagues, have identified some of the sequelae of gastric artery embolization for systemic suppression of the hunger hormone, ghrelin. The researchers have used a porcine model.

News from GEST 2012 US: First-ever live transmission of prostatic artery embolization presented in...

GEST 2012 US delegates had the chance to witness ‰ÛÏfirst-hand‰Û via a live transmission from the University of SÌ£o Paulo Medical School and Sirio Libanes, SÌ£o Paulo, what is being hailed as the first-ever live transmission of a prostatic artery embolization procedure for benign prostatic hyperplasia (BPH).
Interventional News for specialists

Early ASTI results show carotid stenting with embolic protection safe in high-risk surgical patients

The Adapt carotid stent, when used in conjunction with the FilterWire EZ embolic protection device, produced a low and acceptable rate of major adverse events through 30 days postprocedure, according to results presented by Dierk Scheinert at the LINC conference in Germany.
Interventional News for specialists

AngioDynamics to acquire Navilyst Medical for $372 Million

Navilyst Medical is a global medical device company with strengths in the vascular access, interventional radiology and interventional cardiology markets.
Interventional News for specialists

Maquet Cardiovascular completes acquisition of Atrium Medical

Atrium will now operate as an independent, self-contained business unit of Maquet Cardiovascular and retain its current brand name.
Interventional News for specialists

New UAE study finds Contour SE comparable to Embospheres

Spherical PVA has been shown to give adequate uterine fibroid infarction when the appropriate size and endpoint was used in this prospective randomised trial.

Ernst-Peter Strecker

Professor Ernst-Peter Strecker invented his first bare-metal stent in around 1985. He was also one of the first to implant a stent in a...
Interventional News for specialists

Opinion: A review of current embolic agents

Embolotherapy has become an increasingly popular procedure in the field of interventional radiology. The industry has been very active in developing sophisticated embolic agents, Jean-Pierre Pelage and colleagues, share their view.
Interventional News for specialists

New toys for old boys ‰ÛÒ the CLI tool box revisited

Infrapopliteal disease is the most frequent cause of major amputations and this is also one of the vascular regions where currently some of the most exciting endovascular developments emerge. At the TCT meeting, held in Washington, DC, in October 2008, new approaches to infrapopliteal management were clearly given particular attention.

Cook Medical appoints John A Kaufman as chief medical officer

  Cook Medical announces John A Kaufman (Cook Medical, Bloomington, USA) will be joining as its chief medical officer, effective July 2023. With Kaufman’s expertise...

VentureMed to present new data on DCB treatment for PAD

VentureMed Group has announced new data presentations on the treatment of peripheral arterial disease (PAD) with drug-coated balloon (DCBs) in addition to 12-month AV...

First data from BEST-CLI bring surgical bypass into the forefront of discussion for patients...

The first results from the BEST-CLI randomised controlled trial (RCT) of 1,830 patients show that surgical bypass with adequate single-segment great saphenous vein (GSV)...
abstract of the year

Authors receive accolade of ‘Abstract of the Year’ at SIR 2022

At the Society of Interventional Radiology (SIR) 2022 Annual Meeting (11-16 June, Boston, USA), four of the abstracts submitted were declared ‘Abstract of the...
trisalus

TriSalus presents preclinical data on proprietary infusion technology at SIR 2022

TriSalus’ clinical leadership team presented new preclinical data at the Society of Interventional Radiology (SIR) 2022 Annual Scientific Meeting (11–16 June, Boston, USA). The...
christine boone

SIR 2022: Treating placenta accreta spectrum with multivessel pelvic embolization

The findings of a collaborative research project at the University of California San Diego, San Diego, USA were presented in an abstract titled ‘Multivessel...
Ahmed and Ramalingam

Peritransplant vascular complications: An IR approach

In the USA, liver transplantation continues to be the best chance at long-term survival for patients suffering from the sequelae of end-stage liver disease....
David Prologo

New study cites a possible breakthrough treatment in pain management

Damaged nerves can be regenerated with the application of a frozen needle under advanced imaging guidance, according to new research to be presented at...
Douglas Beall

Early study suggests a new, injectable gel may greatly reduce chronic low back pain

An experimental formulation of a hydrogel injected into spinal discs proved safe and effective in substantially relieving chronic low back pain caused by degenerative...
lindsay machan

Minimally invasive treatment could allow more women to conceive without fertility procedures

A simple diagnostic procedure, followed by an interventional radiology treatment known as fallopian tube recanalisation, could allow a high percentage of women struggling with...
kieran murphy

Report recommends taking action within radiology departments to reduce lead dust exposure

‘Surface lead contamination on personal lead radiologic protective apparel’ is a recent report published by Kieran Murphy et al (Toronto Western Hospital, Toronto, Canada)....

New long-term data of paclitaxel devices continue to show no increased mortality compared to...

New long-term data from the SAFE-PAD (Safety assessment of femoropopliteal endovascular treatment with paclitaxel-coated devices) study were presented today as late-breaking clinical research at...
top 10

Interventional News’ top 10 most popular stories for May 2021

Two of our top stories this month come from the International Symposium on Endovascular Therapy (ISET; 9–11 May, Miami, USA), which returned as an...

ACC.21: SAFE-PAD finds no increased risk of death with drug-coated devices used for lower...

Researchers have found no statistically significant difference in mortality between patients treated with drug-coated devices and non-drug-coated devices in the SAFE-PAD study. Eric Secemsky...
value

IRs must “demonstrate the positive impact they have on generating revenue”, SIR discussants urge

During the annual scientific meeting of the Society of Interventional Radiology (SIR; 20–26 March, online), Matthew Hawkins and Raymond Liu jointly hosted a session...

Virtual ACC: Combining aspirin with rivaroxaban reduces risk equally in presence or absence of...

In stable atherosclerosis, a combination of aspirin plus rivaroxaban provided a similar relative degree of benefit on coronary, cerebrovascular, and peripheral endpoints in patients...
artificial intelligence Hackathon winner announced

First SIO artificial intelligence hackathon “mobilises the IO community to enter the era of...

The Society of Interventional Oncology (SIO) hosted its first artificial intelligence (AI) hackathon at this year’s annual meeting (31 January–3 February, New Orleans, USA)....
Centerline

Centerline Biomedical’s surgical positioning system gets FDA clearance

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Centerline Biomedical’s Intra-Operative Positioning System (IOPS), a device used in endovascular procedures...
SCAI

Society for Cardiovascular Angiography and Interventions supports continued use of paclitaxel devices

Experts from the Society for Cardiovascular Angiography and Interventions (SCAI) have reviewed the recent meta-analysis by Katsanos and colleagues and have concluded that the...

US FDA evaluating paclitaxel data, recommend patient surveillance

The impact of the 2018 meta-analysis of randomised paclitaxel-device trials, published in the Journal of the American Heart Association by Konstantinos Katsanos et al,...

Our guidewire design revolutionizes the ability to access even the most tortuous vascular beds

This content is for distribution within USA only. As you pursue new and innovative procedures within more complex anatomy, you need precision and control like...

Experience the Precision and Control

This content is for distribution within USA only. Embozene microspheres are precisely calibrated microspheres engineered for greater embolization control. Unique colored sizing allows for improved...
International registries will help demonstrate the value of interventional oncology therapies

Registries will help determine survival of IO as a specialty

The primary importance of collecting data from registries would be to establish outcome data to prove the value of the interventional oncologic therapies to healthcare...
Interventional News for specialists

BTG and SIO expand Immuno-Oncology / Interventional Oncology grant programme

BTG and the Society of Interventional Oncology (SIO) have expanded their commitment to the Immuno-oncology /interventional oncology research grant programme, by announcing a second...

SIO announces first grants in interventional oncology /immuno-oncology research programme

The Society of Interventional Oncology (SIO and BTG have announced their 2017 Interventional interventional oncology /immuno-oncology research grant recipients. The interventional oncology /immuno-oncology research programme...

Gregory John Slater

"War (as in turf war) is an emotional word because, in wars, people get hurt. I believe we truly care about the patients we...

Constantinos T Sofocleous

“As interventional radiology is established as a free-standing specialty, an international outreach effort to establish guidelines for different interventional treatments is certainly needed,” Constantinos...

Immunotherapy could transform systemic power of locoregional IO treatments

Many physicians now believe that immunotherapy is a disruptive field in cancer medicine. Interventional oncology can either “snooze and lose” as one prominent interventional...
Interventional News for specialists

First patient enrolled in SurModics IDE study of SurVeil drug-coated balloon

SurModics has announced enrolment of the first patient in an early feasibility study of its proprietary SurVeil drug-coated balloon (DCB). A press release states...

ReCor Medical receives IDE approval for RADIANCE-HTN hypertension clinical trial

ReCor Medical has been granted US Food and Drug Administration investigational device exemption approval for the RADIANCE-HTN clinical trial. This trial will measure the...

Cardiovascular Systems reports LIBERTY 360° demographic data in late-breaking presentation at ISET 2016

Cardiovascular Systems has presented baseline demographic data from its LIBERTY 360° post-marked study in a late-breaking presentation at the 28th International Symposium on Endovascular...

Interventional radiologists receive honours from SIR Foundation

Ziv J Haskal, Journal of Vascular and Interventional Radiology editor-in-chief, will receive the Leaders in Innovation Award. The foundation will also bestow Young Investigator, Research and Philanthropy Awards during the Society of Interventional Radiology‰Ûªs (SIR) Annual Scientific Meeting (22‰ÛÒ27 March, San Diego, USA).

Six-month data from LEVANT 2 trial show higher primary patency with drug-coated balloons

LEVANT 2, the first clinical trial in the USA to study the use of drug-coated balloons (CR Bard‰Ûªs Lutonix) for femoropopliteal artery disease, found the procedure is promising for safety and efficacy at six months.
Interventional News for specialists

Society of Interventional Radiology inducts new Fellows

The Society of Interventional Radiology inducted 20 new Fellows during its 37th Annual Scientific Meeting (San Francisco, USA, 24‰ÛÒ29 March 2012).
Interventional News for specialists

First patient enrolled in Lutonix drug-coated balloon pivotal trial

LEVANT 2 is the first drug-coated balloon IDE trial to be approved by the FDA, and is being conducted to support a pre-market application for US approval of the Moxy balloon (Lutonix) for the treatment of peripheral arterial disease.
Interventional News for specialists

‰ÛÏInterpretation‰Û still colours data on carotid artery stenting

Michael R Jaff told delegates at the [email protected] 2011 symposium that it never ceases to amaze him how physicians do not agree on the interpretation of results even when presented with the highest levels of scientific evidence.
Interventional News for specialists

Journal of Vascular and Interventional Radiology increases impact and international reach

Society of Interventional Radiology flagship publication ranks in top half of 90 imaging publications; Society offers journal-only access to professionals outside North America

Brian Stainken

Interventional News’ Co-Editor-in-Chief, and new president of the Society of Interventional Radiology, Brian Stainken, on "organising the aisles" of the interventional superstore, and the...

Afshin Gangi

Professor Afshin Gangi is a well-respected interventional radiologist from the University Hospital of Strasbourg, France. He recently spoke to Interventional News about his career...

Dimitrios Filippiadis

Alban Denys

yasuaki arai

Yasuaki Arai